References
- Jager D, Taverna C, Zippelius A et al. Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. Cancer Immunol. Immunother.53, 144–147 (2004).
- Boon T, Cerottini JC, Van den Eynde B et al. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol.12, 337–365 (1994).
- Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol.5, 987–995 (2004).
- Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature392, 245–252 (1998).
- Shevach EM, DiPaolo RA, Andersson J et al. The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol. Rev.212, 60–73 (2006).
- Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med.10, 909–915 (2004).
- Green JE, Hudson T. The promise of genetically engineered mice for cancer prevention studies. Nat. Rev. Cancer5, 184–198 (2005).
- Lollini PL, Cavallo F, Nanni P et al. Vaccines for tumour prevention. Nat. Rev. Cancer6, 204–216 (2006).
- Viviani S, Jack A, Hall AJ et al. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine17, 2946–2950 (1999).
- Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med.347, 1645–1651 (2002).
- Dhodapkar MV, Krasovsky J, Osman K et al. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J. Exp. Med.198, 1753–1757 (2003).
- Bartkova J, Horejsi Z, Koed K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature434, 864–870 (2005).
- Goulden N, Bader P, Van Der Velden V et al. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br. J. Haematol.122, 24–29 (2003).
- Sramkova L, Muzikova K, Fronkova E et al. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr. Blood Cancer (2006).
- Spisek R, Dhodapkar MV. Immunoprevention of cancer. Hematol. Oncol. Clin. North. Am.20, 735–750 (2006).